Penmenvy

Overview

meningococcal vaccine

vaccine

• non-live vaccine

Avoid/Use Alternative

• interferon gamma 1b
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

interferon gamma 1b

1 interaction

Avoid/Use Alternative

meningococcal vaccine + interferon gamma 1b

avoid combo: combo may result in amplified immune response (immunomodulatory effects)

Monitor/Modify Tx

• abatacept
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

abatacept

1 interaction

Monitor/Modify Tx

meningococcal vaccine + abatacept

if possible, vaccinate at least 2wk before starting abatacept tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• abemaciclib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

abemaciclib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + abemaciclib

if possible, vaccinate at least 2wk before starting abemaciclib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• abrocitinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

abrocitinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + abrocitinib

if possible, vaccinate at least 2wk before starting abrocitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• acalabrutinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

acalabrutinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + acalabrutinib

if possible, vaccinate at least 2wk before starting acalabrutinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• adalimumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

adalimumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + adalimumab

if possible, vaccinate at least 2wk before starting adalimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ado-trastuzumab emtansine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ado-trastuzumab emtansine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ado-trastuzumab emtansine

if possible, vaccinate at least 2wk before starting ado-trastuzumab emtansine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• afamitresgene autoleucel
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

afamitresgene autoleucel

1 interaction

Monitor/Modify Tx

meningococcal vaccine + afamitresgene autoleucel

if possible, vaccinate at least 2wk before starting afamitresgene autoleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• aldesleukin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

aldesleukin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + aldesleukin

if possible, vaccinate at least 2wk before starting aldesleukin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• alemtuzumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

alemtuzumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + alemtuzumab

if possible, vaccinate at least 2wk before starting alemtuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• amivantamab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

amivantamab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + amivantamab

if possible, vaccinate at least 2wk before starting amivantamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anakinra
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

anakinra

1 interaction

Monitor/Modify Tx

meningococcal vaccine + anakinra

if possible, vaccinate at least 2wk before starting anakinra tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anifrolumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

anifrolumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + anifrolumab

if possible, vaccinate at least 2wk before starting anifrolumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anti-thymocyte globulin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + anti-thymocyte globulin

if possible, vaccinate at least 2wk before starting anti-thymocyte globulin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• asciminib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

asciminib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + asciminib

if possible, vaccinate at least 2wk before starting asciminib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• atezolizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

atezolizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + atezolizumab

if possible, vaccinate at least 2wk before starting atezolizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• atidarsagene autotemcel
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

meningococcal vaccine + atidarsagene autotemcel

if possible, vaccinate at least 6wk before myeloablative conditioning or after hematologic recovery: combo may result in inadequate vaccine response (immunosuppressive effects)

• avelumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

avelumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + avelumab

if possible, vaccinate at least 2wk before starting avelumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• avutometinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

avutometinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + avutometinib

if possible, vaccinate at least 2wk before starting avutometinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• axicabtagene ciloleucel
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

axicabtagene ciloleucel

1 interaction

Monitor/Modify Tx

meningococcal vaccine + axicabtagene ciloleucel

if possible, vaccinate at least 2wk before starting axicabtagene ciloleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• azacitidine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

azacitidine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + azacitidine

if possible, vaccinate at least 2wk before starting azacitidine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• azathioprine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

azathioprine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + azathioprine

if possible, vaccinate at least 2wk before starting azathioprine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• baricitinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

baricitinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + baricitinib

if possible, vaccinate at least 2wk before starting baricitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• basiliximab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

basiliximab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + basiliximab

if possible, vaccinate at least 2wk before starting basiliximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belantamab mafodotin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

belantamab mafodotin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + belantamab mafodotin

if possible, vaccinate at least 2wk before starting belantamab mafodotin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belatacept
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

belatacept

1 interaction

Monitor/Modify Tx

meningococcal vaccine + belatacept

if possible, vaccinate at least 2wk before starting belatacept tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belimumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

belimumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + belimumab

if possible, vaccinate at least 2wk before starting belimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belinostat
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

belinostat

1 interaction

Monitor/Modify Tx

meningococcal vaccine + belinostat

if possible, vaccinate at least 2wk before starting belinostat tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• belzutifan
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

belzutifan

1 interaction

Monitor/Modify Tx

meningococcal vaccine + belzutifan

if possible, vaccinate at least 2wk before starting belzutifan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• bendamustine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

bendamustine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + bendamustine

if possible, vaccinate at least 2wk before starting bendamustine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• betamethasone
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

betamethasone

1 interaction

Monitor/Modify Tx

meningococcal vaccine + betamethasone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• bimekizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

bimekizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + bimekizumab

if possible, vaccinate at least 2wk before starting bimekizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• blinatumomab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

blinatumomab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + blinatumomab

if possible, vaccinate at least 2wk before starting blinatumomab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• bortezomib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

bortezomib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + bortezomib

if possible, vaccinate at least 2wk before starting bortezomib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• brentuximab vedotin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

brentuximab vedotin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + brentuximab vedotin

if possible, vaccinate at least 2wk before starting brentuximab vedotin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• brexucabtagene autoleucel
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

brexucabtagene autoleucel

1 interaction

Monitor/Modify Tx

meningococcal vaccine + brexucabtagene autoleucel

if possible, vaccinate at least 2wk before starting brexucabtagene autoleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• brodalumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

brodalumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + brodalumab

if possible, vaccinate at least 2wk before starting brodalumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• budesonide
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

budesonide

1 interaction

Monitor/Modify Tx

meningococcal vaccine + budesonide

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• budesonide rectal
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

budesonide rectal

1 interaction

Monitor/Modify Tx

meningococcal vaccine + budesonide rectal

consider vaccinating at least 2wk before budesonide rectal use; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• busulfan
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

busulfan

1 interaction

Monitor/Modify Tx

meningococcal vaccine + busulfan

if possible, vaccinate at least 2wk before starting busulfan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cabazitaxel
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

cabazitaxel

1 interaction

Monitor/Modify Tx

meningococcal vaccine + cabazitaxel

if possible, vaccinate at least 2wk before starting cabazitaxel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• canakinumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

canakinumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + canakinumab

if possible, vaccinate at least 2wk before starting canakinumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• capecitabine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

capecitabine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + capecitabine

if possible, vaccinate at least 2wk before starting capecitabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• capmatinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

capmatinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + capmatinib

if possible, vaccinate at least 2wk before starting capmatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• carboplatin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

carboplatin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + carboplatin

if possible, vaccinate at least 2wk before starting carboplatin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• carfilzomib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

carfilzomib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + carfilzomib

if possible, vaccinate at least 2wk before starting carfilzomib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• carmustine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

carmustine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + carmustine

if possible, vaccinate at least 2wk before starting carmustine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cemiplimab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

cemiplimab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + cemiplimab

if possible, vaccinate at least 2wk before starting cemiplimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• certolizumab pegol
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

certolizumab pegol

1 interaction

Monitor/Modify Tx

meningococcal vaccine + certolizumab pegol

if possible, vaccinate at least 2wk before starting certolizumab pegol tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• chlorambucil
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

chlorambucil

1 interaction

Monitor/Modify Tx

meningococcal vaccine + chlorambucil

if possible, vaccinate at least 2wk before starting chlorambucil tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ciltacabtagene autoleucel
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ciltacabtagene autoleucel

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ciltacabtagene autoleucel

if possible, vaccinate at least 2wk before starting ciltacabtagene autoleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cisplatin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

cisplatin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + cisplatin

if possible, vaccinate at least 2wk before starting cisplatin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cladribine injection
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

cladribine injection

1 interaction

Monitor/Modify Tx

meningococcal vaccine + cladribine injection

if possible, vaccinate at least 2wk before starting cladribine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cladribine oral
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

cladribine oral

1 interaction

Monitor/Modify Tx

meningococcal vaccine + cladribine oral

if possible, vaccinate at least 2wk before starting cladribine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• clofarabine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

clofarabine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + clofarabine

if possible, vaccinate at least 2wk before starting clofarabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• copanlisib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

copanlisib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + copanlisib

if possible, vaccinate at least 2wk before starting copanlisib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• corticotropin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

corticotropin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + corticotropin

if possible, vaccinate at least 2wk before starting corticotropin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cortisone
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

cortisone

1 interaction

Monitor/Modify Tx

meningococcal vaccine + cortisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• cosibelimab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

cosibelimab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + cosibelimab

if possible, vaccinate at least 2wk before starting cosibelimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cyclophosphamide
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

meningococcal vaccine + cyclophosphamide

if possible, vaccinate at least 2wk before starting cyclophosphamide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cyclosporine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

cyclosporine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + cyclosporine

if possible, vaccinate at least 2wk before starting cyclosporine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cytarabine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

cytarabine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + cytarabine

if possible, vaccinate at least 2wk before cytarabine start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dactinomycin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

dactinomycin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + dactinomycin

if possible, vaccinate at least 2wk before starting dactinomycin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• daratumumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

daratumumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + daratumumab

if possible, vaccinate at least 2wk before starting daratumumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dasatinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

dasatinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + dasatinib

if possible, vaccinate at least 2wk before starting dasatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• daunorubicin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

daunorubicin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + daunorubicin

if possible, vaccinate at least 2wk before daunorubicin start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• decitabine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

decitabine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + decitabine

if possible, vaccinate at least 2wk before starting decitabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• defactinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

defactinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + defactinib

if possible, vaccinate at least 2wk before starting defactinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• deflazacort
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

deflazacort

1 interaction

Monitor/Modify Tx

meningococcal vaccine + deflazacort

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• delgocitinib topical
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

delgocitinib topical

1 interaction

Monitor/Modify Tx

meningococcal vaccine + delgocitinib topical

if possible, vaccinate at least 2wk before starting delgocitinib topical tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• deucravacitinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

deucravacitinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + deucravacitinib

if possible, vaccinate at least 2wk before starting deucravacitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• deuruxolitinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + deuruxolitinib

if possible, vaccinate at least 2wk before starting deuruxolitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dexamethasone
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

dexamethasone

1 interaction

Monitor/Modify Tx

meningococcal vaccine + dexamethasone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• dimethyl fumarate
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

dimethyl fumarate

1 interaction

Monitor/Modify Tx

meningococcal vaccine + dimethyl fumarate

if possible, vaccinate at least 2wk before starting dimethyl fumarate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dinutuximab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

dinutuximab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + dinutuximab

if possible, vaccinate at least 2wk before starting dinutuximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• diroximel fumarate
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

diroximel fumarate

1 interaction

Monitor/Modify Tx

meningococcal vaccine + diroximel fumarate

if possible, vaccinate at least 2wk before starting diroximel fumarate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• docetaxel
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

docetaxel

1 interaction

Monitor/Modify Tx

meningococcal vaccine + docetaxel

if possible, vaccinate at least 2wk before starting docetaxel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dordaviprone
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

dordaviprone

1 interaction

Monitor/Modify Tx

meningococcal vaccine + dordaviprone

if possible, vaccinate at least 2wk before starting dordaviprone tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dostarlimab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

dostarlimab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + dostarlimab

if possible, vaccinate at least 2wk before starting dostarlimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• doxorubicin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

doxorubicin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + doxorubicin

if possible, vaccinate at least 2wk before starting doxorubicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dupilumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

dupilumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + dupilumab

if possible, vaccinate at least 2wk before starting dupilumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• durvalumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

durvalumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + durvalumab

if possible, vaccinate at least 2wk before starting durvalumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• duvelisib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

duvelisib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + duvelisib

if possible, vaccinate at least 2wk before starting duvelisib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• efgartigimod alfa
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

efgartigimod alfa

1 interaction

Monitor/Modify Tx

meningococcal vaccine + efgartigimod alfa

if possible, vaccinate at least 2wk before starting efgartigimod alfa tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• elivaldogene autotemcel
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

elivaldogene autotemcel

1 interaction

Monitor/Modify Tx

meningococcal vaccine + elivaldogene autotemcel

if possible, vaccinate at least 6wk before myeloablative conditioning or after hematologic recovery: combo may result in inadequate vaccine response (immunosuppressive effects)

• elotuzumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

elotuzumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + elotuzumab

if possible, vaccinate at least 2wk before starting elotuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• elranatamab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

elranatamab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + elranatamab

if possible, vaccinate at least 2wk before starting elranatamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• emapalumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

emapalumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + emapalumab

if possible, vaccinate at least 2wk before starting emapalumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• epcoritamab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

epcoritamab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + epcoritamab

if possible, vaccinate at least 2wk before starting epcoritamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• epirubicin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

epirubicin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + epirubicin

if possible, vaccinate at least 2wk before starting epirubicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• erdafitinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

erdafitinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + erdafitinib

if possible, vaccinate at least 2wk before starting erdafitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• eribulin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

eribulin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + eribulin

if possible, vaccinate at least 2wk before starting eribulin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• etanercept
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

etanercept

1 interaction

Monitor/Modify Tx

meningococcal vaccine + etanercept

if possible, vaccinate at least 2wk before starting etanercept tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• etoposide
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

etoposide

1 interaction

Monitor/Modify Tx

meningococcal vaccine + etoposide

if possible, vaccinate at least 2wk before etoposide start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• etrasimod
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

etrasimod

1 interaction

Monitor/Modify Tx

meningococcal vaccine + etrasimod

if possible, vaccinate at least 2wk before starting etrasimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• etuvetidigene autotemcel
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

etuvetidigene autotemcel

1 interaction

Monitor/Modify Tx

meningococcal vaccine + etuvetidigene autotemcel

if possible, vaccinate at least 6wk before myeloablative conditioning or after hematologic recovery: combo may result in inadequate vaccine response (immunosuppressive effects)

• everolimus
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

everolimus

1 interaction

Monitor/Modify Tx

meningococcal vaccine + everolimus

if possible, vaccinate at least 2wk before starting everolimus tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fam-trastuzumab deruxtecan
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

fam-trastuzumab deruxtecan

1 interaction

Monitor/Modify Tx

meningococcal vaccine + fam-trastuzumab deruxtecan

if possible, vaccinate at least 2wk before starting fam-trastuzumab deruxtecan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fingolimod
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

fingolimod

1 interaction

Monitor/Modify Tx

meningococcal vaccine + fingolimod

if possible, vaccinate at least 2wk before starting fingolimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• floxuridine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

floxuridine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + floxuridine

if possible, vaccinate at least 2wk before starting floxuridine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fludarabine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

fludarabine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + fludarabine

if possible, vaccinate at least 2wk before starting fludarabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fludrocortisone
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

fludrocortisone

1 interaction

Monitor/Modify Tx

meningococcal vaccine + fludrocortisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• fluorouracil
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

fluorouracil

1 interaction

Monitor/Modify Tx

meningococcal vaccine + fluorouracil

if possible, vaccinate at least 2wk before fluorouracil start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• fruquintinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

fruquintinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + fruquintinib

if possible, vaccinate at least 2wk before starting fruquintinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• futibatinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

futibatinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + futibatinib

if possible, vaccinate at least 2wk before starting futibatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• gemcitabine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

gemcitabine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + gemcitabine

if possible, vaccinate at least 2wk before starting gemcitabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• gemtuzumab ozogamicin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

gemtuzumab ozogamicin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + gemtuzumab ozogamicin

if possible, vaccinate at least 2wk before starting gemtuzumab ozogamicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• glofitamab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

glofitamab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + glofitamab

if possible, vaccinate at least 2wk before starting glofitamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• golimumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

golimumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + golimumab

if possible, vaccinate at least 2wk before starting golimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• guselkumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

guselkumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + guselkumab

if possible, vaccinate at least 2wk before starting guselkumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• hydrocortisone
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

hydrocortisone

1 interaction

Monitor/Modify Tx

meningococcal vaccine + hydrocortisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• hydroxyurea
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

hydroxyurea

1 interaction

Monitor/Modify Tx

meningococcal vaccine + hydroxyurea

if possible, vaccinate at least 2wk before starting hydroxyurea tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ibritumomab tiuxetan
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ibritumomab tiuxetan

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ibritumomab tiuxetan

if possible, vaccinate at least 2wk before starting ibritumomab tiuxetan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ibrutinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ibrutinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ibrutinib

if possible, vaccinate at least 2wk before starting ibrutinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• icotrokinra
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

icotrokinra

1 interaction

Monitor/Modify Tx

meningococcal vaccine + icotrokinra

if possible, vaccinate at least 2wk before icotrokinra start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• idarubicin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

idarubicin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + idarubicin

if possible, vaccinate at least 2wk before starting idarubicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• idecabtagene vicleucel
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

idecabtagene vicleucel

1 interaction

Monitor/Modify Tx

meningococcal vaccine + idecabtagene vicleucel

if possible, vaccinate at least 2wk before starting idecabtagene vicleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• idelalisib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

idelalisib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + idelalisib

if possible, vaccinate at least 2wk before starting idelalisib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ifosfamide
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ifosfamide

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ifosfamide

if possible, vaccinate at least 2wk before starting ifosfamide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• imatinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

imatinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + imatinib

if possible, vaccinate at least 2wk before starting imatinib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• inebilizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

inebilizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + inebilizumab

if possible, vaccinate at least 4wk before starting inebilizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• infliximab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

infliximab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + infliximab

if possible, vaccinate at least 2wk before starting infliximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• inotuzumab ozogamicin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

inotuzumab ozogamicin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + inotuzumab ozogamicin

if possible, vaccinate at least 2wk before starting inotuzumab ozogamicin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ipilimumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ipilimumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ipilimumab

if possible, vaccinate at least 2wk before starting ipilimumab; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• irinotecan
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

irinotecan

1 interaction

Monitor/Modify Tx

meningococcal vaccine + irinotecan

if possible, vaccinate at least 2wk before starting irinotecan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• isatuximab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

isatuximab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + isatuximab

if possible, vaccinate at least 2wk before starting isatuximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ixabepilone
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ixabepilone

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ixabepilone

if possible, vaccinate at least 2wk before starting ixabepilone tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ixekizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ixekizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ixekizumab

if possible, vaccinate at least 2wk before starting ixekizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lazertinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

lazertinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + lazertinib

if possible, vaccinate at least 2wk before starting lazertinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lebrikizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

lebrikizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + lebrikizumab

if possible, vaccinate at least 2wk before starting lebrikizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• leflunomide
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

leflunomide

1 interaction

Monitor/Modify Tx

meningococcal vaccine + leflunomide

if possible, vaccinate at least 2wk before starting leflunomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lenalidomide
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

lenalidomide

1 interaction

Monitor/Modify Tx

meningococcal vaccine + lenalidomide

if possible, vaccinate at least 2wk before starting lenalidomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• linvoseltamab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

linvoseltamab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + linvoseltamab

if possible, vaccinate at least 2wk before starting linvoseltamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lisocabtagene maraleucel
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

lisocabtagene maraleucel

1 interaction

Monitor/Modify Tx

meningococcal vaccine + lisocabtagene maraleucel

if possible, vaccinate at least 2wk before starting lisocabtagene maraleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lomustine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

lomustine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + lomustine

if possible, vaccinate at least 2wk before starting lomustine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• loncastuximab tesirine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

loncastuximab tesirine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + loncastuximab tesirine

if possible, vaccinate at least 2wk before starting loncastuximab tesirine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lurbinectedin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

lurbinectedin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + lurbinectedin

if possible, vaccinate at least 2wk before starting lurbinectedin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• lymphocyte immune globulin, anti-thymocyte globulin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + lymphocyte immune globulin, anti-thymocyte globulin

if possible, vaccinate at least 2wk before starting anti-thymocyte globulin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• margetuximab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

margetuximab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + margetuximab

if possible, vaccinate at least 2wk before starting margetuximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• melphalan
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

melphalan

1 interaction

Monitor/Modify Tx

meningococcal vaccine + melphalan

if possible, vaccinate at least 2wk before starting melphalan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mercaptopurine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

mercaptopurine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + mercaptopurine

if possible, vaccinate at least 2wk before starting mercaptopurine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• methotrexate
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

methotrexate

1 interaction

Monitor/Modify Tx

meningococcal vaccine + methotrexate

if possible, vaccinate at least 2wk before starting methotrexate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• methylprednisolone
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

methylprednisolone

1 interaction

Monitor/Modify Tx

meningococcal vaccine + methylprednisolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• mirikizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

mirikizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + mirikizumab

if possible, vaccinate at least 2wk before starting mirikizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mitomycin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

mitomycin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + mitomycin

if possible, vaccinate at least 2wk before starting mitomycin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mitoxantrone
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

mitoxantrone

1 interaction

Monitor/Modify Tx

meningococcal vaccine + mitoxantrone

if possible, vaccinate at least 2wk before starting mitoxantrone tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mogamulizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

mogamulizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + mogamulizumab

if possible, vaccinate at least 2wk before starting mogamulizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• momelotinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

momelotinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + momelotinib

if possible, vaccinate at least 2wk before starting momelotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• monomethyl fumarate
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

monomethyl fumarate

1 interaction

Monitor/Modify Tx

meningococcal vaccine + monomethyl fumarate

if possible, vaccinate at least 2wk before starting monomethyl fumarate tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mosunetuzumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

mosunetuzumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + mosunetuzumab

if possible, vaccinate at least 2wk before starting mosunetuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mycophenolate mofetil
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

meningococcal vaccine + mycophenolate mofetil

if possible, vaccinate at least 2wk before starting mycophenolate mofetil tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mycophenolic acid
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

meningococcal vaccine + mycophenolic acid

if possible, vaccinate at least 2wk before starting mycophenolic acid tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• natalizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

natalizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + natalizumab

if possible, vaccinate at least 2wk before starting natalizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nelarabine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

nelarabine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + nelarabine

if possible, vaccinate at least 2wk before starting nelarabine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nemolizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

nemolizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + nemolizumab

if possible, vaccinate at least 2wk before starting nemolizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nilotinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

nilotinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + nilotinib

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nipocalimab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

nipocalimab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + nipocalimab

if possible, vaccinate at least 2wk before starting nipocalimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• nivolumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

nivolumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + nivolumab

if possible, vaccinate at least 2wk before starting nivolumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• obecabtagene autoleucel
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

obecabtagene autoleucel

1 interaction

Monitor/Modify Tx

meningococcal vaccine + obecabtagene autoleucel

if possible, vaccinate at least 2wk before starting obecabtagene autoleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• obinutuzumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

obinutuzumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + obinutuzumab

if possible, vaccinate at least 2wk before starting obinutuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ocrelizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ocrelizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ocrelizumab

if possible, vaccinate at least 2wk before starting ocrelizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ofatumumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ofatumumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ofatumumab

if possible, vaccinate at least 2wk before starting ofatumumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• olaparib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

olaparib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + olaparib

if possible, vaccinate at least 2wk before starting olaparib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• oxaliplatin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

oxaliplatin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + oxaliplatin

if possible, vaccinate at least 2wk before starting oxaliplatin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ozanimod
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ozanimod

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ozanimod

if possible, vaccinate at least 2wk before starting ozanimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• paclitaxel
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

paclitaxel

1 interaction

Monitor/Modify Tx

meningococcal vaccine + paclitaxel

if possible, vaccinate at least 2wk before starting paclitaxel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• palbociclib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

palbociclib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + palbociclib

if possible, vaccinate at least 2wk before starting palbociclib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• peginterferon alfa 2a
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

peginterferon alfa 2a

1 interaction

Monitor/Modify Tx

meningococcal vaccine + peginterferon alfa 2a

if possible, vaccinate at least 2wk before starting peginterferon alfa 2a tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pembrolizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

pembrolizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + pembrolizumab

if possible, vaccinate at least 2wk before starting pembrolizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pemetrexed
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

pemetrexed

1 interaction

Monitor/Modify Tx

meningococcal vaccine + pemetrexed

if possible, vaccinate at least 2wk before starting pemetrexed; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• penpulimab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

penpulimab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + penpulimab

if possible, vaccinate at least 2wk before starting penpulimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pentostatin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

pentostatin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + pentostatin

if possible, vaccinate at least 2wk before starting pentostatin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pertuzumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

pertuzumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + pertuzumab

if possible, vaccinate at least 2wk before starting pertuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pirtobrutinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + pirtobrutinib

if possible, vaccinate at least 2wk before starting pirtobrutinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pneumococcal vaccine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

pneumococcal vaccine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + pneumococcal vaccine

complete pneumococcal vaccine series >4wk before starting meningococcal vaccine series in asplenic pts: combo may decr. immunologic response to pneumococcal vaccine if administered <4wk apart (mechanism unknown)

• polatuzumab vedotin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

polatuzumab vedotin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + polatuzumab vedotin

if possible, vaccinate at least 2wk before starting polatuzumab vedotin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• pomalidomide
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

pomalidomide

1 interaction

Monitor/Modify Tx

meningococcal vaccine + pomalidomide

if possible, vaccinate at least 2wk before starting pomalidomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ponatinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ponatinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ponatinib

if possible, vaccinate at least 2wk before starting ponatinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ponesimod
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ponesimod

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ponesimod

if possible, vaccinate at least 2wk before starting ponesimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• prednisolone
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

prednisolone

1 interaction

Monitor/Modify Tx

meningococcal vaccine + prednisolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• prednisone
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

prednisone

1 interaction

Monitor/Modify Tx

meningococcal vaccine + prednisone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• procarbazine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

procarbazine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + procarbazine

if possible, vaccinate at least 2wk before starting procarbazine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• regorafenib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

regorafenib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + regorafenib

if possible, vaccinate at least 2wk before starting regorafenib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• retifanlimab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

retifanlimab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + retifanlimab

if possible, vaccinate at least 2wk before starting retifanlimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• revumenib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

revumenib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + revumenib

if possible, vaccinate at least 2wk before starting revumenib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rilonacept
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

rilonacept

1 interaction

Monitor/Modify Tx

meningococcal vaccine + rilonacept

if possible, vaccinate at least 2wk before starting rilonacept tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rilzabrutinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

rilzabrutinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + rilzabrutinib

if possible, vaccinate at least 2wk before starting rilzabrutinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ripretinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ripretinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ripretinib

if possible, vaccinate at least 2wk before starting ripretinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• risankizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

risankizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + risankizumab

if possible, vaccinate at least 2wk before starting risankizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ritlecitinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ritlecitinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ritlecitinib

if possible, vaccinate at least 2wk before starting ritlecitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rituximab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

rituximab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + rituximab

vaccinate at least 4wk before starting rituximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• romidepsin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

romidepsin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + romidepsin

if possible, vaccinate at least 2wk before starting romidepsin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ropeginterferon alfa-2b
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ropeginterferon alfa-2b

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ropeginterferon alfa-2b

if possible, vaccinate at least 2wk before starting ropeginterferon alfa-2b tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rozanolixizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

rozanolixizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + rozanolixizumab

if possible, vaccinate at least 2wk before starting rozanolixizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• rucaparib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

rucaparib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + rucaparib

if possible, vaccinate at least 2wk before starting rucaparib; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ruxolitinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ruxolitinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ruxolitinib

if possible, vaccinate at least 2wk before starting ruxolitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sarilumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

sarilumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + sarilumab

if possible, vaccinate at least 2wk before starting sarilumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• satralizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

satralizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + satralizumab

if possible, vaccinate at least 2wk before starting satralizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• secukinumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

secukinumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + secukinumab

if possible, vaccinate at least 2wk before starting secukinumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• selinexor
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

selinexor

1 interaction

Monitor/Modify Tx

meningococcal vaccine + selinexor

if possible, vaccinate at least 2wk before starting selinexor tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• selumetinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

selumetinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + selumetinib

if possible, vaccinate at least 2wk before starting selumetinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sevabertinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

sevabertinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + sevabertinib

if possible, vaccinate at least 2wk before starting sevabertinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sibeprenlimab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

sibeprenlimab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + sibeprenlimab

if possible, vaccinate at least 2wk before starting sibeprenlimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• siltuximab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

siltuximab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + siltuximab

if possible, vaccinate at least 2wk before starting siltuximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• siponimod
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

siponimod

1 interaction

Monitor/Modify Tx

meningococcal vaccine + siponimod

if possible, vaccinate at least 2wk before starting siponimod tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sirolimus
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

sirolimus

1 interaction

Monitor/Modify Tx

meningococcal vaccine + sirolimus

if possible, vaccinate at least 2wk before starting sirolimus tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sirolimus albumin-bound
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

meningococcal vaccine + sirolimus albumin-bound

if possible, vaccinate at least 2wk before starting sirolimus albumin-bound tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sirolimus topical
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

sirolimus topical

1 interaction

Monitor/Modify Tx

meningococcal vaccine + sirolimus topical

if possible, vaccinate at least 2wk before starting sirolimus tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sorafenib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

sorafenib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + sorafenib

if possible, vaccinate at least 2wk before starting sorafenib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• spesolimab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

spesolimab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + spesolimab

if possible, vaccinate at least 2wk before starting spesolimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sunitinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

sunitinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + sunitinib

if possible, vaccinate at least 2wk before starting sunitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• sunvozertinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

sunvozertinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + sunvozertinib

if possible, vaccinate at least 2wk before starting sunvozertinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tacrolimus
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

tacrolimus

1 interaction

Monitor/Modify Tx

meningococcal vaccine + tacrolimus

if possible, vaccinate at least 2wk before starting tacrolimus tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tafasitamab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

tafasitamab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + tafasitamab

if possible, vaccinate at least 2wk before starting tafasitamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• taletrectinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

taletrectinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + taletrectinib

if possible, vaccinate at least 2wk before starting taletrectinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• talquetamab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

talquetamab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + talquetamab

if possible, vaccinate at least 2wk before starting talquetamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tarlatamab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

tarlatamab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + tarlatamab

if possible, vaccinate at least 2wk before starting tarlatamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• teclistamab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

teclistamab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + teclistamab

if possible, vaccinate at least 2wk before starting teclistamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• telisotuzumab vedotin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

telisotuzumab vedotin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + telisotuzumab vedotin

if possible, vaccinate at least 2wk before starting telisotuzumab vedotin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• temozolomide
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

temozolomide

1 interaction

Monitor/Modify Tx

meningococcal vaccine + temozolomide

if possible, vaccinate at least 2wk before starting temozolomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• temsirolimus
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

temsirolimus

1 interaction

Monitor/Modify Tx

meningococcal vaccine + temsirolimus

if possible, vaccinate at least 2wk before temsirolimus start; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• teplizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

teplizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + teplizumab

vaccinate at least 2wk before or 6wk after teplizumab tx; otherwise, consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• teriflunomide
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

teriflunomide

1 interaction

Monitor/Modify Tx

meningococcal vaccine + teriflunomide

if possible, vaccinate at least 2wk before starting teriflunomide tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• thioguanine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

thioguanine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + thioguanine

if possible, vaccinate at least 2wk before starting thioguanine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• thiotepa
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

thiotepa

1 interaction

Monitor/Modify Tx

meningococcal vaccine + thiotepa

if possible, vaccinate at least 2wk before starting thiotepa tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tildrakizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

tildrakizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + tildrakizumab

if possible, vaccinate at least 2wk before starting tildrakizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tisagenlecleucel
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

tisagenlecleucel

1 interaction

Monitor/Modify Tx

meningococcal vaccine + tisagenlecleucel

if possible, vaccinate at least 2wk before starting tisagenlecleucel tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tislelizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

tislelizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + tislelizumab

if possible, vaccinate at least 2wk before starting tislelizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tocilizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

tocilizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + tocilizumab

if possible, vaccinate at least 2wk before starting tocilizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tofacitinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

tofacitinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + tofacitinib

if possible, vaccinate at least 2wk before starting tofacitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• topotecan
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

topotecan

1 interaction

Monitor/Modify Tx

meningococcal vaccine + topotecan

if possible, vaccinate at least 2wk before starting topotecan tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• toripalimab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

toripalimab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + toripalimab

if possible, vaccinate at least 2wk before starting toripalimab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• trabectedin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

trabectedin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + trabectedin

if possible, vaccinate at least 2wk before starting trabectedin; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tralokinumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

tralokinumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + tralokinumab

if possible, vaccinate at least 2wk before starting tralokinumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• trastuzumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

trastuzumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + trastuzumab

if possible, vaccinate at least 2wk before starting trastuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tremelimumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

tremelimumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + tremelimumab

if possible, vaccinate at least 2wk before starting tremelimumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• triamcinolone
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

triamcinolone

1 interaction

Monitor/Modify Tx

meningococcal vaccine + triamcinolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• ublituximab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ublituximab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ublituximab

if possible, vaccinate at least 2wk before starting ublituximab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• upadacitinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

upadacitinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + upadacitinib

if possible, vaccinate at least 2wk before starting upadacitinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ustekinumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ustekinumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ustekinumab

if possible, vaccinate at least 2wk before starting ustekinumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vamorolone
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

vamorolone

1 interaction

Monitor/Modify Tx

meningococcal vaccine + vamorolone

if possible, vaccinate at least 2wk before starting long-term (>2wk) high-dose systemic steroids; consider post-immunization titer check: combo may result in inadequate vaccine response (immunosuppressive effects)

• vandetanib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

vandetanib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + vandetanib

if possible, vaccinate at least 2wk before starting vandetanib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vedolizumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

vedolizumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + vedolizumab

if possible, vaccinate at least 2wk before starting vedolizumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• venetoclax
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

venetoclax

1 interaction

Monitor/Modify Tx

meningococcal vaccine + venetoclax

if possible, vaccinate at least 2wk before starting venetoclax tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vinblastine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

vinblastine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + vinblastine

if possible, vaccinate at least 2wk before starting vinblastine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vincristine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

vincristine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + vincristine

if possible, vaccinate at least 2wk before starting vincristine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• vinorelbine
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

vinorelbine

1 interaction

Monitor/Modify Tx

meningococcal vaccine + vinorelbine

if possible, vaccinate at least 2wk before starting vinorelbine tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• voclosporin
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

voclosporin

1 interaction

Monitor/Modify Tx

meningococcal vaccine + voclosporin

if possible, vaccinate at least 2wk before starting voclosporin tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• zanidatamab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

zanidatamab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + zanidatamab

if possible, vaccinate at least 2wk before starting zanidatamab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• zanubrutinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

zanubrutinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + zanubrutinib

if possible, vaccinate at least 2wk before starting zanubrutinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• zenocutuzumab
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

zenocutuzumab

1 interaction

Monitor/Modify Tx

meningococcal vaccine + zenocutuzumab

if possible, vaccinate at least 2wk before starting zenocutuzumab tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ziftomenib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

ziftomenib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + ziftomenib

if possible, vaccinate at least 2wk before starting ziftomenib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• zongertinib
Penmenvy (meningococcal groups ACWY diphtheria CRM197 conjugate and meningococcal group B vaccine (MenACWY-CRM/ MenB-4C) )

+

zongertinib

1 interaction

Monitor/Modify Tx

meningococcal vaccine + zongertinib

if possible, vaccinate at least 2wk before starting zongertinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)